ProKidney (id:5299 PROK)
1.69 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 11:26:57 AM)
Exchange closed, opens in 1 day 22 hours
About ProKidney
Market Capitalization 1.81B
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
| Headquarters (address) |
2000 Frontis Plaza Blvd. Winston-Salem 27103 NC United States |
| Phone | 336 999 7028 |
| Website | https://www.prokidney.com |
| Employees | 163 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | PROK |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.18 - 4.44 |
| Market Capitalization | 1.81B |
| Dividend yield forward | 250.89 % |
| Dividend yield forward United States (ID:6, base:1866) | 4.15 % |
| P/E trailing | -2.96 |
| P/E forward | -3.32 |
| Price/Book | 0.481 |
| Beta | 1.30 |
| EPS | -0.540 |
| EPS United States (ID:6, base:3400) | 24.26 |
Forward Annual Dividend Yield
Forward Annual Dividend Yield: ProKidney has raised their dividend 250.89 years in a row. This is below the 41189.366600 year average in the 'Biotechnology' industry
Forward Annual Dividend Yield
Forward Annual Dividend Yield: ProKidney has raised their dividend 250.89 years in a row. This is below the 41189.366600 year average in the 'Biotechnology' industry